ScreenerHero

PSTVPlus Therapeutics, Inc.

Data unavailable
NAS · US · Healthcare · Biotechnology · plustherapeutics.com
3.838USD+1.80%Mkt Cap: 26.64M $P/E: 0.18

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rh…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap26.64M $
Enterprise Value12.25M $
Revenue (TTM)5.18M $
Gross Profit-4.31M $
Net Income (TTM)-22.39M $
Revenue/Share1.120 USD
Last Price3.838 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees28
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS72941H4002
Valuation
P/E (Trailing)0.18
P/E (Forward)-1.62
PEG2.45
EV/EBITDA-0.66
EV/Revenue2.36
P/S5.14
P/B2.22
EPS (TTM)21.56
EPS (Forward)-2.40
52W Range
2.9005% of range23.50
52W High23.50 USD
52W Low2.900 USD
Profitability
Gross Margin-83.09%
Oper. Margin-692.51%
EBITDA Margin0.00%
Profit Margin-230.24%
ROE-560.21%
ROA-137.13%
Growth
Revenue Growth-2.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-20.77M $
CapEx (TTM)67.00K $
FCF Margin-291.55%
FCF Yield-56.71%
Net Debt-14.39M $
Net Debt/EBITDA0.78
Balance Sheet
Debt/Equity0.21
Current Ratio2.27
Quick Ratio2.07
Book Value/Sh1.743 USD
Cash/Share2.196 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateApr 2, 2026
Analyst Consensus
Rating—
Target (Mean)36.00 USD
Upside (mean)+838.0%
Target Range12.00 USD – 57.00 USD
$12.00+838.0% to mean$57.00
# Analysts4
Ownership
Shares Out.6.88M
Float6.46M
Insiders1.84%
Institutions13.87%
Short Interest
Short Ratio3.0d
Short % Float10.35%
Short % Out.10.30%
Shares Short709.38K
Short (prev mo.)1.12M
Technical
SMA 504.297 (-10.7%)
SMA 2007.837 (-51.0%)
Beta1.42
S&P 52W Chg18.16%
Avg Vol (30d)159.17K
Avg Vol (10d)80.84K
Technical Indicators
RSI (14)46.1
MACD-0.1633
MACD Signal-0.2190
MACD Hist.+0.0556
BB Upper4.220 USD
BB Middle3.849 USD
BB Lower3.478 USD
BB Width19.29%
ATR (14)0.3076 USD
Vol Ratio (20d)0.58x